Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment

A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Immunotherapeutic regulation of the tumor microenvironment in prostate cancer patients is not understood. Most antibody immunotherapies have not succeeded in prostate cancer. We showed previously that high-ris...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
Stereotactic body radiotherapy (SBRT) is an increasingly used radiation modality for the treatment of both localized and metastatic prostate cancer. Substantial data suggests that prostate cancer may be more sensitive to higher doses of radiation per fraction due to its low α/β ratio. This increased sensitivity raises important questions as to how SBRT should be combined with systemic therapy for clinically significant prostate cancer, including whether androgen deprivation therapy retains its beneficial effects when combined with SBRT. Furthermore, pre-clinical and clinical data suggest pronounced immunomodulat...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract Prostate cancer (PCa) is the fourth most common cancer in the world and treatment is currently based on surgical removal and/or radiotherapy and/or hormone therapy. In the last few years' immunotherapy has become an important cancer treatment option. While the principles of immunotherapy evolved, only sipuleucel-T was approved by the Food and Drug Administration (FDA) which lead to further studies with other agents, starting a new era in immuno-oncology. A number of vaccines are under clinical investigation as well as checkpoint inhibitors. Despite the current enthusiasm, it is unlikely that any of the ap...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Tags: Actas Urol Esp Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
Authors: Ba Dziul D, Jakubczyk P, Chotorlishvili L, Toklikishvilie Z, Traciak J, Jakubowicz-Gil J, Chmiel-Szajner S Abstract Basic immunology research over several decades has led to an improved understanding of tumour recognition by components of the immune system and mechanism of tumour evasion from immune detection. These findings have ultimately led to creating antitumour immunotherapies in patients with different kind of cancer including prostate cancer. The increasing number of reports confirms that immune-based therapies have clinical benefit in patients with prostate cancer with potentially less toxicity in...
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Tags: Comput Math Methods Med Source Type: research
36Objectives: Due to a markedly immunosuppressive tumor microenvironment (TME), immunotherapy has had limited success in prostate cancer (PCa). Radiation therapy, which has shown to remodel the TME of irradiated tumors towards a more immune-susceptible phenotype even at low radiation doses of 2-3 Gy, is limited to the localized disease setting. Our goal is to demonstrate that systemically delivered targeted radionuclide therapy (TRT) using [90Y]Y-NM600 provides beneficial immunomodulatory effects that may enhance the response of PCa to immunotherapies. Methods: Male FVB mice bearing syngeneic prostate Myc-CaP tumor allogra...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Center for Therapy Excellence YIA Symposium Source Type: research
Condition:   Prostate Cancer Interventions:   Biological: W_pro1;   Drug: Cemiplimab;   Drug: Goserelin acetate Sponsor:   Biontech RNA Pharmaceuticals GmbH Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX ™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid p hosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of an...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Authors: Thana M, Wood L Abstract Although immune-mediated therapies have been used in genitourinary (gu) malignancies for decades, recent advances with monoclonal antibody checkpoint inhibitors (cpis) have led to a number of promising treatment options. In renal cell carcinoma (rcc), cpis have been shown to have benefit over conventional therapies in a number of settings, and they are the standard of care for many patients with metastatic disease. Based on recent data, combinations of cpis and antiangiogenic therapies are likely to become a new standard approach in rcc. In urothelial carcinoma, cpis have been show...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions: Most cases, whether primary or metastatic, harboured therapeutically relevant alterations, including those associated with PARP inhibitor sensitivity, immunotherapy sensitivity and resistance to androgen pathway targeting agents. The observed intra-patient heterogeneity and presence of genomic alterations in multiple growth pathways in individual cases suggests that a precision medicine model in prostate cancer needs to simultaneously incorporate multiple pathway-targeting agents. Our whole genome approach allowed for structural variant assessment in addition to the ability to rapidly reassess an individual&am...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Prostate Cancer | Study | Yervoy